MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing SLK, a tri-specific Nanobody designed to inhibit IL-17A and IL-17F for inflammatory skin and joint diseases. The company has no approved products or product revenue yet and is preparing for late-stage regulatory filing and potential commercialization, initially in hidradenitis suppurativa and related inflammatory indications.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaSLK is the company's single proprietary therapeutic candidate for inflammatory skin and joint diseases.
Ongoing and planned trials in HS, PsA, adolescent HS, axSpA and PPP support the lead asset's label expansion.
Activities include BLA preparation, manufacturing planning, and launch infrastructure build-out.
Asiakkaat
MoonLake does not yet sell commercial products, so its near-term 'customers' are regulators, clinical investigators, and future prescribers and payors that will determine whether SLK can be approved and adopted. If approved, the company expects demand from dermatology and rheumatology specialists treating patients with moderate-to-severe inflammatory skin and joint diseases.
FDA, EMA and other agencies review clinical data and determine whether SLK can be marketed.
Dermatologists treating moderate-to-severe HS would prescribe SLK if it is approved and differentiated on efficacy or durability.
Rheumatologists treating PsA and axSpA are future prescribers for label expansion beyond HS.
Insurers and reimbursement bodies will influence uptake because the product is expected to compete at a premium price.
Hospitals, clinics and investigators run the studies that generate the evidence needed for approval.
Strategia
The company is focused on completing late-stage development of SLK, filing a BLA, and building the operational capabilities needed for a U.S. launch. It is also expanding its intellectual property position and may broaden the pipeline or in-license additional assets to reduce single-asset dependence over time.
Approval depends on successful Phase 3 data and a clean safety profile in the target inflammatory indications.
The company needs to convert clinical data into a BLA and establish the commercial infrastructure for first sales.
A single-asset biotech depends on patent protection and license durability to preserve future pricing power and value.
Additional indications or assets could reduce concentration risk and extend the company's growth runway.
Maantiede
MoonLake is headquartered in Zug, Switzerland, but is organized as a Cayman Islands company and operates a multinational development footprint. Its current business is concentrated in the U.S. and Europe through clinical trials, regulatory interactions, and office presence in Switzerland, the U.K. and Portugal, with future commercialization expected to begin in the United States.
Riskit
MoonLake is highly dependent on a single clinical asset, so trial failure, safety issues, or regulatory setbacks would have an outsized impact on value. The company also faces financing, manufacturing, IP, and commercialization risks typical of development-stage biotech, with added exposure to premium pricing pressure and reimbursement hurdles if SLK reaches market.
- Clinical development failure for SLKVaikutus: KriittinenTodennäköisyys: Korkea
The company has no approved products and depends on positive Phase 3 outcomes to create value.
Kohdistuu - Financing and dilution riskVaikutus: KorkeaTodennäköisyys: Korkea
Development and launch spending exceed current operating cash generation, so future funding may be required.
Kohdistuu: Pre-commercial R&D and launch build-out
- Safety or tolerability issuesVaikutus: KorkeaTodennäköisyys: Kohtalainen
An unfavorable safety profile could prevent approval or reduce physician and payer adoption.
Kohdistuu: All SLK indications
- License and IP dependenceVaikutus: KorkeaTodennäköisyys: Kohtalainen
Rights to SLK are licensed, so breach or failure to meet diligence obligations could impair commercialization rights.
Kohdistuu: MHKDG and RCT license arrangements
- Manufacturing and supply chain riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
The company relies on third parties for SLK production and clinical supply.
Kohdistuu: Contract manufacturing and clinical supply chain
- Commercial adoption and reimbursement riskVaikutus: KeskitasoTodennäköisyys: Kohtalainen
SLK is expected to launch at a premium price, which may slow uptake versus established biologics and biosimilars.
Kohdistuu: Future U.S. and ex-U.S. launch
Kirjanpito
Harkinnanvaraiset erätThe company has not generated product revenue, so future revenue timing will depend on approval, launch and any milestone or license income.
Vaikutus: No current sales base; future periods may be volatile when commercialization begins
Clinical trial, CRO and manufacturing costs are expensed as incurred and require judgment around accrual completeness.
Vaikutus: Can shift quarterly operating loss and cash burn
Equity awards to employees and directors create non-cash expense and dilution effects.
Vaikutus: Affects reported loss and per-share metrics
Purchase obligations mainly relate to CRO and contract manufacturing agreements and must be tracked for liquidity planning.
Vaikutus: Important for future cash requirements
Office leases in Zug, Cambridge and Porto and the Loan and Security Agreement create fixed obligations and interest expense.
Vaikutus: Affects leverage, liquidity and future cash flows
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Oruka Therapeutics, Inc.
ORKA · Pharmaceutical Preparations
Aclaris Therapeutics, Inc.
ACRS · Pharmaceutical Preparations
Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing small and large molecule therapies for immuno-inflammatory diseases.
Monopar Therapeutics
MNPR · Pharmaceutical Preparations
Monopar Therapeutics is a U.S.-based clinical-stage biopharmaceutical company developing drug candidates for Wilson disease and advanced cancers.
Cel-Sci Corporation
CVM · Biological Products, (No Diagnostic Substances)
Immuneering Corp
IMRX · Pharmaceutical Preparations
Immuneering Corp is a clinical-stage biotechnology company focused on developing oncology therapies, with an emphasis on MAPK pathway cancers and biomarker-driven patient selection.
Spyre Therapeutics, Inc.
SYRE · Pharmaceutical Preparations
Spyre Therapeutics is a U.S.-based clinical-stage biotechnology company focused on developing long-acting antibody therapies for inflammatory bowel disease and rheumatic diseases.
Päivitetty: 24.9.2026